A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab

CompletedOBSERVATIONAL
Enrollment

221

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
Psoriatic Arthritis
Interventions
DRUG

Ustekinumab

All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.

Trial Locations (1)

69437

Hôpital Edouard Herriot, Lyon

All Listed Sponsors
lead

Janssen Cilag S.A.S.

INDUSTRY

NCT03336281 - A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab | Biotech Hunter | Biotech Hunter